Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 5Terminated 4Withdrawn 2Not yet recruiting 2Active not recruiting 2Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stage I Mixed Cell Type Kidney Wilms Tumor 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 28pembrolizumab 24cabozantinib 22Ipilimumab 19Specimen Handling 14Magnetic Resonance Spectroscopy 13Axitinib 12lenvatinib 10Radiosurgery 9belzutifan 8CTLA-4 Antigen 7Biopsy 7atezolizumab 6cemiplimab 5Radiotherapy 5Bevacizumab 5toripalimab 4Everolimus 4Blood Specimen Collection 4avelumab 3aldesleukin 3X-Rays 3Sunitinib 3Standard of Care 3Paclitaxel 3zimberelimab 2trastuzumab deruxtecan 2tivozanib 2spartalizumab 2pazopanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Renal Cell × Nephrectomy × Clear all
NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Sun Yat-sen University

Phase 3 Recruiting
298 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡